Ionis Pharmaceuticals(IONS) - 2025 Q3 - Quarterly Results

Financial Performance - TRYNGOLZA® generated $32 million in net product sales in Q3 2025, a nearly 70% increase over the prior quarter[1] - Total revenue for Q3 2025 was $157 million, a 17% increase compared to $134 million in Q3 2024[3] - Operating expenses for Q3 2025 were $317 million, up 14% from $282 million in Q3 2024[3] - Ionis increased its full-year 2025 revenue guidance to $875-900 million, up from the previous guidance of $825-850 million[5] - Total revenue for the three months ended September 30, 2025, was $157 million, an increase from $134 million in the same period of 2024, representing a 17% growth[37] - Commercial revenue reached $116 million in Q3 2025, up from $76 million in Q3 2024, marking a 53% increase[37] - Research and development revenue for the nine months ended September 30, 2025, was $446 million, compared to $272 million in the same period of 2024, reflecting a 64% increase[37] - The net loss for Q3 2025 was $129 million, slightly improved from a net loss of $140 million in Q3 2024[37] - Non-GAAP net loss for the nine months ended September 30, 2025, was $61 million, compared to $256 million in the same period of 2024[38] Product Development and Clinical Trials - Olezarsen demonstrated a statistically significant reduction in fasting triglycerides of up to 72% in Phase 3 studies[9] - Zilganersen showed a mean difference of 33.3% in gait speed compared to control at week 61 in a pivotal study[11] - Ionis achieved regulatory approval for Donidalorsen in the U.S. for HAE and for TRYNGOLZA in the EU for FCS in 2025[42] - The company launched new products including DAWNZERA and TRYNGOLZA in the U.S. in 2025[42] - Ionis has ongoing Phase 3 clinical trials for multiple programs, including Olezarsen for sHTG and Zilganersen for Alexander disease, with key data expected in 2026[42] Cash and Assets - Cash, cash equivalents, and short-term investments were over $2.1 billion as of September 30, 2025, compared to approximately $2.0 billion previously[5] - Cash, cash equivalents, and short-term investments totaled $2.24 billion as of September 30, 2025, down from $2.30 billion at the end of 2024[41] - Total assets increased to $3.03 billion as of September 30, 2025, compared to $3.00 billion at the end of 2024[41] Future Outlook - Ionis anticipates achieving cash flow breakeven in 2028, driven by growth in product revenues and partner revenues[6] - The company earned a $280 million upfront payment for the global license of sapablursen in Q2 2025[8] - SPINRAZA® generated global sales of $374 million in Q3 2025, contributing to total royalty revenue of $76 million for the quarter[12]